- Steady as she goes, milestones recognised and passed
- Cash position, very strong and spending frugal and highly targeted
- no need to approach the market, if institutions want script, then buy on market
- Stage 2 ....results very promising
- stage 3 enrolling...............the rubber hits the road with Specificity, Sensitivity figures
- Gen 2 arising
- Focus on the FDA around the skeleton of the final submission
- Market 2025..........................and then......................
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.06 |
Change
0.020(0.98%) |
Mkt cap ! $175.5M | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.06 | $2.02 | $13.80K | 6.752K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2635 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.06 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |